AstraZeneca PLC (AZN)

Market Cap	281.66B +28.9%
Revenue (ttm)	60.44B +9.9%
Net Income	10.39B +33.7%
EPS	6.64 +33.6%
Shares Out	1.55B
PE Ratio	27.11
Forward PE	17.14
Dividend	$3.20 (1.76%)
Ex-Dividend Date	Feb 20, 2026

Volume	1,379,470
Open	183.25
Previous Close	184.96
Day's Range	180.55 - 183.44
52-Week Range	134.14 - 212.71
Beta	0.22
Analysts	Strong Buy
Price Target	224.49 (0.0%)
Earnings Date	Apr 29, 2026

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 12, 1993
• Employees: 95,100
• Stock Exchange: NYSE
• Ticker Symbol: AZN
• Website: https://www.astrazeneca.com

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Analyst Summary

According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is no change of 0.00% from the latest price.

Price Target

$224.49

( upside)

Analyst Consensus: Strong Buy